|
Diuretic therapy in HFrEF, AF ablation, TACT 2 and the story of subgroups, and SGLT2 inhibitor underuse are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Diuretic Therapy in HF - Dapa vs Metolazone Trial https://doi.org/10.1093/eurheartj/ehad341 ADVOR https://www.nejm.org/doi/10.1056/NEJMoa2203094
II. Rapid Medication Titration for Acute HF - ACC Decision Pathway https://www.jacc.org/doi/10.1016/j.jacc.2024.06.002
III. SGLT2 Inhibitor Use in the US - Shin and Colleagues; JACC https://www.sciencedirect.com/science/article/abs/pii/S0735109724076332
- Editorial https://doi.org/10.1016/j.jacc.2024.07.001
IV. AF Ablation: General Anesthesia vs Conscious Sedation - Da Riis-Vestergaard and Colleagues https://doi.org/10.1093/europace/euae203
V. TACT 2 Published - TACT 1 https://jamanetwork.com/journals/jama/fullarticle/1672238
- TACT 1 DM https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000663
- TACT 2 https://jamanetwork.com/journals/jama/fullarticle/2822472
You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net |